Geode Capital Management, LLC Cingulate Inc. Transaction History

Geode Capital Management, LLC

  • $1.21 Trillion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023
BUY
$0.52 - $0.98 $67 - $126
129 Added 0.23%
55,795 $39,000
Q2 2023

Aug 11, 2023
SELL
$0.84 - $1.12 $41,458 - $55,277
-49,355 Reduced 47.0%
55,666 $51,000
Q1 2023

May 15, 2023
BUY
$0.91 - $1.85 $95,569 - $194,288
105,021 New
105,021 $102,000

About Cingulate Inc.

CING Quotes by TradingView
  • Ticker CING
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,309,400
  • Market Cap $49M
  • Description
  • Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-de...
More about CING
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email